G2GBIO Inc. (KOSDAQ:456160)

South Korea flag South Korea · Delayed Price · Currency is KRW
82,800
+5,000 (6.43%)
At close: Jan 16, 2026
187.17%
Market Cap1.44T
Revenuen/a
Net Incomen/a
Shares Out16.42M
EPSn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,191,497
Average Volume1,011,922
Open74,900
Previous Close77,800
Day's Range72,500 - 90,400
52-Week Range27,567 - 107,700
Betan/a
RSI60.42
Earnings Daten/a

About G2GBIO

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company’s pipeline products includes GB-5001, GB-5001A, and GB-5112 for the treatment of alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal c... [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456160
Full Company Profile

News

There is no news available yet.